Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Prepaid Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Prepaid Assets for 10 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 52.5% to $61.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $61.0 million, a 52.5% increase, with the full-year FY2025 number at $61.0 million, up 52.5% from a year prior.
  • Prepaid Assets was $61.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $53.2 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $77.5 million in Q2 2022 to a low of $40.0 million in Q4 2024.
  • A 5-year average of $59.2 million and a median of $61.1 million in 2025 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: plummeted 35.15% in 2023, then soared 52.5% in 2025.
  • Ultragenyx Pharmaceutical's Prepaid Assets stood at $71.7 million in 2021, then decreased by 3.93% to $68.9 million in 2022, then plummeted by 30.92% to $47.6 million in 2023, then decreased by 15.99% to $40.0 million in 2024, then soared by 52.5% to $61.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Prepaid Assets are $61.0 million (Q4 2025), $53.2 million (Q3 2025), and $61.2 million (Q2 2025).